US stocks drop as FDA rejects lung cancer drug approval

Summit Therapeutics shares fall 14% after US FDA rejects lung cancer drug ivonescimab.

By ·

Nov 16, 2026

7 cards · 1m · tap to begin

From · · · 1m

US stocks drop as FDA rejects lung cancer drug approval

Summit Therapeutics shares fall 14% after US FDA rejects lung cancer drug ivonescimab.

In brief

Summit Therapeutics shares fall 14% after US FDA rejects lung cancer drug ivonescimab. US FDA declined to approve Summit Therapeutics' lung cancer drug ivonescimab, causing shares to drop 14%. Originally reported by The Economic Times.

FDA rejects lung cancer drug

US Food and Drug Administration declined to approve Summit Therapeutics' experimental lung cancer drug ivonescimab.

Shares drop 14%

Summit Therapeutics shares fell 14% at $12.16 in morning trading after FDA decision.

Drug study results

Late-stage study showed no statistically significant overall survival benefit for ivonescimab.

Regional patient outcomes

Follow-up data showed greater survival benefit in Chinese patients than North American and European patients.

FDA's regulatory impact

FDA decision sets meaningful regulatory precedent for lung cancer drug class with implications for Bristol Myers Squibb, BioNTech, Pfizer, Merck and AbbVie.

Drug mechanism

Ivonescimab targets proteins PD-1 and VEGF to help tumors evade immune system and spread.

Investor reaction

Investors await first-line trial data comparing ivonescimab against Merck's Keytruda for lung cancer treatment.

The key point

US FDA declined to approve Summit Therapeutics' lung cancer drug ivonescimab, causing shares to drop 14%.

Read the original on The Economic Times

Read the TL;DR — this story on one card.

How we make summaries

React

Sign in to react and comment.

Comments (0)

Life is short. Keep it sweet. Respect others' opinions and be kind!

    Recommended next

    More decks on us stocks and related topics.